Bioxyne Locks in $50M German Cannabis Supply Deal With $25M Committed in Year One
Bioxyne locks in $50 million German supply deal with ADREX, securing $25 million commitment in year one
Bioxyne Limited (ASX: BXN), through its wholly owned subsidiary Breathe Life Sciences (BLS), has entered a two-year, $50 million supply agreement with ADREXpharma GmbH for GMP-manufactured medicinal cannabis products in Germany. The agreement includes a $25 million minimum purchase commitment in the first 12 months, with automatic renewal for a further 12 months. This represents a material expansion on the initial supply agreement executed with Adrex in June 2025, deepening an already established commercial relationship in Europe’s largest medicinal cannabis market.
When big ASX news breaks, our subscribers know first
What this agreement means for Bioxyne investors
Key commercial terms at a glance
| Term | Detail |
|---|---|
| Agreement value | $50 million (two-year total) |
| Year 1 minimum commitment | $25 million minimum purchase commitment in the first 12 months |
| Duration | 24 months |
| Renewal terms | Automatic renewal for a further 12 months |
| Exclusivity granted | ADREXpharma granted exclusive rights in Germany to distribute the Dr Watson® brand |
| Products supplied | BLS’s Australian GMP-manufactured cannabis flower and other products |
Distribution is underpinned by Adrex’s established pharmacy and healthcare network across the German market, providing a defined sales pathway and near-term revenue visibility for BXN.
Understanding what GMP certification means for investors
Good Manufacturing Practice (GMP) is a globally recognised regulatory standard that governs the quality, consistency, and safety of pharmaceutical product manufacturing. In plain terms, it means a facility is independently certified to produce medicines that meet the quality thresholds required by regulated health authorities.
GMP certification is effectively the entry ticket to regulated European pharmaceutical supply chains. Products that are not GMP-certified cannot legally access these markets, regardless of their quality or origin. This creates a meaningful barrier to entry that non-certified cannabis suppliers cannot overcome.
BLS holds an Australian GMP licence, which is the direct commercial enabler of this German agreement. That certification gives BXN a structural advantage over non-certified competitors seeking to supply into Germany’s tightly regulated pharmaceutical sector.
Germany’s medicinal cannabis market, and why BXN is moving fast
Germany is Europe’s largest and most developed medicinal cannabis market, with annual volumes now estimated at more than 200 tonnes per annum, according to ADREXpharma Chief Executive Officer Nicole Broockmann. That scale, combined with evolving regulatory frameworks and increasing patient demand, has made Germany a priority focus for BXN’s international growth strategy.
Europe, and specifically Germany and the United Kingdom, remains a key geographic focus for the company. BXN’s intent is not limited to cannabis supply. Chief Executive Officer Sam Watson has signalled that the company is actively progressing opportunities in additional medicines and controlled substances, positioning the German agreement as part of a broader pharmaceutical platform-building strategy.
Sam Watson, Chief Executive Officer, Bioxyne Limited
“This expanded supply agreement with Adrex reflects the scale and momentum we are building in new markets and strengthens our position across key regulated European markets as we continue to grow our broader pharmaceutical portfolio.”
Nicole Broockmann, Chief Executive Officer, ADREXpharma GmbH
“This agreement positions both companies to build a scalable platform capable of becoming a significant supplier into Germany’s rapidly expanding medicinal cannabis market, which is now estimated at more than 200 tonnes per annum.”
The next major ASX story will hit our subscribers first
Bioxyne’s broader platform: cannabis today, wider therapeutics tomorrow
BLS’s global manufacturing and distribution footprint
BLS is a GMP-licensed manufacturer, wholesaler, importer, and exporter of controlled substances (S3, S4, S8, S9). Its operational presence spans multiple international jurisdictions, supporting the scalability required to deliver on agreements of this size.
BLS operational locations include:
- Sydney, New South Wales (corporate head office)
- Queensland, Australia (manufacturing, warehousing, import/export)
- Nagoya, Japan
- Scotland, United Kingdom
- Prague, Czechia
Beyond medicinal cannabis, BLS’s product scope includes Psilocybin and MDMA, positioning the subsidiary as a diversified controlled substances manufacturer with a pipeline that extends well beyond its current largest commercial category.
The Dr Watson® brand and the road ahead
ADREXpharma’s exclusive rights in Germany to the Dr Watson® brand represent a targeted brand penetration strategy in one of Europe’s most developed regulated pharmaceutical markets. The Dr Watson® brand is owned by BLS across the United Kingdom, Japan, Australia, and New Zealand. Germany now joins this portfolio as an exclusively licensed market through the Adrex arrangement.
Management has stated its intent to continue progressing opportunities in additional medicines and controlled substances, using the established cannabis supply and distribution platform as a commercial foundation. The Adrex agreement provides a tangible, revenue-backed anchor for that strategy in a market with the scale and regulatory maturity to support long-term growth.
Don’t Miss the Next Healthcare Breakout on the ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of the market the moment announcements hit. Click the “Free Alerts” button at StockWire X to start receiving real-time alerts today.